1. Home
  2. LCTX vs DOUG Comparison

LCTX vs DOUG Comparison

Compare LCTX & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LCTX
  • DOUG
  • Stock Information
  • Founded
  • LCTX 1990
  • DOUG 1911
  • Country
  • LCTX United States
  • DOUG United States
  • Employees
  • LCTX N/A
  • DOUG N/A
  • Industry
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • DOUG Building operators
  • Sector
  • LCTX Health Care
  • DOUG Real Estate
  • Exchange
  • LCTX Nasdaq
  • DOUG Nasdaq
  • Market Cap
  • LCTX 165.6M
  • DOUG 166.2M
  • IPO Year
  • LCTX N/A
  • DOUG N/A
  • Fundamental
  • Price
  • LCTX $0.91
  • DOUG $1.66
  • Analyst Decision
  • LCTX Strong Buy
  • DOUG
  • Analyst Count
  • LCTX 3
  • DOUG 0
  • Target Price
  • LCTX $5.67
  • DOUG N/A
  • AVG Volume (30 Days)
  • LCTX 409.3K
  • DOUG 764.4K
  • Earning Date
  • LCTX 08-08-2024
  • DOUG 11-05-2024
  • Dividend Yield
  • LCTX N/A
  • DOUG N/A
  • EPS Growth
  • LCTX N/A
  • DOUG N/A
  • EPS
  • LCTX N/A
  • DOUG N/A
  • Revenue
  • LCTX $6,186,000.00
  • DOUG $951,674,000.00
  • Revenue This Year
  • LCTX N/A
  • DOUG $3.85
  • Revenue Next Year
  • LCTX $119.00
  • DOUG $17.40
  • P/E Ratio
  • LCTX N/A
  • DOUG N/A
  • Revenue Growth
  • LCTX N/A
  • DOUG N/A
  • 52 Week Low
  • LCTX $0.77
  • DOUG $1.00
  • 52 Week High
  • LCTX $1.61
  • DOUG $3.16
  • Technical
  • Relative Strength Index (RSI)
  • LCTX 52.00
  • DOUG 44.02
  • Support Level
  • LCTX $0.83
  • DOUG $1.42
  • Resistance Level
  • LCTX $0.94
  • DOUG $1.91
  • Average True Range (ATR)
  • LCTX 0.06
  • DOUG 0.17
  • MACD
  • LCTX 0.01
  • DOUG -0.05
  • Stochastic Oscillator
  • LCTX 64.77
  • DOUG 29.56

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

About DOUG Douglas Elliman Inc.

Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees.

Share on Social Networks: